Empagliflozin, Pioglitazone or Glimepiride as Third Agents with Metformin + DPP‑4 Inhibitor: Similar HbA1c Drops but Different Trade‑offs
Highlights
– In a multicentre, open‑label, phase 4 randomized trial, adding empagliflozin (10 mg), pioglitazone (15 mg) or glimepiride (2 mg) to metformin plus a DPP‑4 inhibitor produced similar mean HbA1c reductions at 24 weeks (≈0.8–0.9%).
– Glycaemic target attainment (HbA1c <7.0%) was similar across arms (57–66%).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.